Formulation and Evaluation of Modified Liposome for Transdermal Drug

Objective: Pramipexole is widely used in the treatment of anti-Parkinson’s, however it is associated with several side effects so the objective was to develop liposomal drug delivery of Pramipexole and thus reduce its side effect and toxicity and improve bioavaibility, efficacy and therapeutic index. Further study to modify drug delivery and to determine effect of stearylamine and sodium cholate content on the liposomal characteristics was investigated.Methods: In the present study the modified liposomes were prepared by using Pramipexole, phosphotidylcholine, cholesterol, stearylamine and sodium cholate in different ratio. These liposomes were prepared using thin film hydration method and characterized for vesicle size, drug entrapment studies, in-vitro release, and zeta potential, ex-vivo study.Results: The preparation of pramipexole loaded liposome was initiated by studying the influencing of drug lipid ratio on drug entrapment in vesicles. The drug bearing capacity of liposome was found to be invariably dependent on drug lipid ratio employed in liposomal composition, then formulation addition of stearylamine and sodium cholate to determine penetration enhancer. Modified liposome of optimized liposomal batches was formulated. Further modified liposomes were evaluated for entrapment efficiency, in-vitro release, zeta potential, and vesicle size. Thus, positive charged liposome seen to be promising as carrier for pramipexole drug thought transdermal drug delivery system.Conclusion: Incorporation of stearylamine enhanced the percent entrapment of pramipexole owing to rigidizaton effect on the membrane packing. Modified Liposomes of pramipexole can be promising carriers for the effective treatment of Parkinson’s.